Table 7 Cumulative cost analysis of all blood products (nā=ā55 patients with CPB timeāā„ā115āmin)
From: Thrombelastometry guided blood-component therapy after cardiac surgery: a randomized study
Variables | CONTROL | ROTEMĀ® |
|---|---|---|
Number | 26 (47%) | 29 (53%) |
intraoperative | ||
āRBCs (unit: 70 ā¬) | 2520 | 2240 |
āFFPs (unit: 51 ā¬) | 1530 | 1020 |
āPlatelet concentrates (unit: 500 ā¬) | 4000 | 1500 |
āFibrinogen (1āg: 287.5 ā¬) | 1438 | 1150 |
āPPSB (500āIU: 120 ā¬) | 1200 | 1080 |
āAT3 (1000āIU: 70 ā¬) | 350 | 245 |
āAprotinin (2.5 Mio IU 123.75 ā¬) | 668 | 2574 |
āTranexamic acid (500āmg: 7.63 ā¬) | 595 | 732 |
Cumulative costs [ā¬] | 12,301 | 10,541 |
ICU (after randomization) | ||
āRBCs (unit: 70 ā¬) | 12,460 | 7140 |
āFFPs (unit: 51 ā¬) | 5304 | 2397 |
āPlatelet concentrates (unit: 500 ā¬) | 13,000 | 5000 |
āFibrinogen (1āg: 287.5 ā¬) | 1150 | 6900 |
āPPSB (500āIU: 120 ā¬) | 0 | 0 |
āAT3 (1000āIU: 70 ā¬) | 70 | 0 |
āAprotinin (2.5 Mio IU: 123.75 ā¬) | 495 | 0 |
āTranexamic acid (500āmg: 7.63 ā¬) | 31 | 31 |
Cumulative costs [ā¬] | 32,510 | 21,468 |
Overall cumulative costs [ā¬] | 44,811 | 32,009 |
Costs per patient [ā¬] | 1723.5 | 1103.8 |
Costs savings per patient [ā¬] | ā | 619.8 |